Initializing

Gaining access to millions of annotated cells across 10+ cancer indications.

Analyzing pathology slides

Our algorithms detect and characterize tissue and cell architecture.

Calculating Features

Cell & area locations are intersected to compute over hundreds of complex feature values.

Predicting Response

Deep-learning models combining spatial features and clinical data drive the discovery of pathology based spatial biomarkers.

Initializing

Gaining access to millions of annotated cells across 10+ cancer indications.

Analyzing pathology slides

Our algorithms detect and characterize tissue and cell architecture.

Calculating Features

Cell & area locations are intersected to compute over hundreds of complex feature values.

Predicting Response

Deep-learning models combining spatial features and clinical data drive the discovery of pathology based spatial biomarkers.

We are transforming precision medicine with AI-powered pathology

Our team’s work is a unique collaboration of experienced AI technologists, physicians and exceptional healthcare research professionals.

Exploratory Research Platform

Our Platform empowers researchers to discover novel, human interpretable pathology-based biomarkers that predict response to therapy, identify genomic markers or explain complex biological phenomena at scale.

AI-Powered Clinical Trial Assays

Qualified biomarkers are incorporated into prospective clinical trials via Nucleai’s AI-powered digital assays. In partnership with CROs and central laboratories, we support a compliant (FDA, CLIA, GxP) and scalable patient selection process.

Companion Diagnostics Development

In partnership with biopharma, diagnostics and clinical laboratories, we develop and deploy Nucleai’s digital assays as companion diagnostics across the world, providing physicians with the best diagnostic tools to improve patient lives.

Our Platform

Nucleai’s platform unlocks spatial insights. In Nucleai Atom, your pathology slides are transformed into raw data of cell and area locations. The raw data is fed into the Nucleai engine, computing hundreds of spatial features intersected with outcome to predict drug response.

DATA & INSTITUTIONAL PARTNERS

INVESTORS

SCIENTIFIC PUBLICATIONS

LEADERSHIP

CAREERS

Join Us in Biomarker Discovery

At Nucleai, we bring physicians and researchers cutting edge AI-based technology that identifies pathology-based biomarkers that can predict response to therapy and significantly improve patient outcomes. Come join our team of experienced AI engineers, world renowned clinicians, and others, to revolutionize precision medicine and make a major impact.
Algorithms Team Lead

Algorithms Team Lead

Tel Aviv

Director of Application Science

Director of Application Science

United States

Director of Translational Medicine

Director of Translational Medicine

Tel Aviv

Full-stack Software Engineer Team Lead

Full-stack Software Engineer Team Lead

Tel Aviv

Medical Data Specialist Full Time

Medical Data Specialist Full Time

Tel Aviv

Program Manager

Program Manager

Tel Aviv

Senior Data Scientist

Senior Data Scientist

Tel Aviv

Senior Product Manager

Senior Product Manager

Tel Aviv

Senior Product Marketing Manager

Senior Product Marketing Manager

United States

NEWS & UPDATES

Nucleai and Mayo Clinic BioPharma Diagnostics Announce Strategic Collaboration to Transform Digital Pathology for Drug Development and Clinical Practice

[Chicago, Illinois] – Nucleai, a leading provider of artificial intelligence (AI) solutions for pathology and spatial biology, and Mayo Clinic BioPharma Diagnostics are pleased to announce a strategic collaboration to bring world-class digital pathology solutions, technologies, and services to support drug development and clinical practice. This collaboration combines Nucleai’s AI-powered spatial biology technology with Mayo’s […]

Read More

Nucleai and Adlai Nortye Partner to Identify and Validate Novel Spatial Biomarkers Across Adlai Clinical Trials

CHICAGO–(BUSINESS WIRE)–Nucleai, a leader in AI-powered spatial biology, and Adlai Nortye, a global biopharmaceutical company focused on developing innovative immuno-oncology therapies, today announced a strategic partnership to identify, validate and test novel H&E-based biomarkers across Adlai Nortye’s Phase 2 and 3 clinical trials. The collaboration will initially focus on identifying subjects that could derive benefit […]

Read More

Spatial Multiomics Powers Pathology Prediction

Spatial multiomics, still in its discovery phase, can mean different things to different people. It typically denotes the visualization of transcriptomic and proteomic data in the context of tissue architecture, either directly on the same section or on serial sections that are integrated computationally. Spatial multiomics may eventually grow to encompass lipids, glycans, metabolites, epigenetic […]

Read More

Nucleai Launches New Multiplex Imaging Spatial Analysis Solution to Increase Reliability and Speed of Immunofluorescence Analysis for Drug Discovery and Development

Nucleai, a leader in AI-powered spatial biology, today announced the expansion of its spatial biology platform to include a new generation of multiplex immunofluorescence (mIF) analysis that uses deep learning to establish new levels of accuracy, speed, and generalizability, further unlocking the power of mIF data for drug discovery and development. Nucleai will present new […]

Read More

Add Your Heading Text Here